Table 3.
Comparing IC50s of inhibitors to Galactokinase (GALK), Mevalonate kinase (MVK), Homoserine kinase (HSK), CDP-ME kinase, Glucokinase and Hexokinase
| GALK (μM) | MVK (μM) | HSK (μM) | CDP-ME kinase(μM) | Glucokinase/Hexokinase (μM) | GALK (μM) | MVK (μM) | HSK (μM) | CDP-ME kinase(μM) | Glucokinase/Hexokinase (μM) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.7 | >60 | >60 | >60 | >60 | 18 | 12.5 | 23 | >60 | >60 | >60 |
| 3 | 10.5 | 24.5 | >60 | >60 | >60 | 20 | 25 | 13 | >60 | 5.5 | >60 |
| 4 | 1.5 | >60 | >60 | >60 | >60 | 21 | 18.5 | 15 | >60 | 5.5 | >60 |
| 5 | 12 | 20 | >60 | 18 | >60 | 22 | 30 | 21.3 | >60 | >60 | >60 |
| 6 | 16.5 | >60 | >60 | >60 | >60 | 23 | 11.5 | >60 | >60 | >60 | >60 |
| 8 | 24 | 25.2 | >60 | 5 | >60 | 24 | 6.3 | >60 | >60 | >60 | >60 |
| 9 | 5.2 | 8.2 | >60 | 11 | >60 | 26 | 19.3 | 11.5 | >60 | >60 | >60 |
| 10 | 6.5 | 10.3 | 15.8 | >60 | >60 | 27 | 32 | 30 | >60 | >60 | >60 |
| 11 | 33.3 | 40 | >60 | >60 | >60 | 28 | 20 | 21 | >60 | >60 | >60 |
| 13 | 33.3 | 20 | >60 | 17 | >60 | 30 | 21.1 | 14.5 | >60 | >60 | Weak inhibition for Glucokinase |
| 14 | 27.1 | 16 | >60 | >60 | >60 | 31 | 21 | 18.5 | >60 | >60 | >60 |
| 16 | 30 | 40 | >60 | Not tested | >60 | 32 | 20.3 | >60 | >60 | >60 | >60 |
| 17 | 12.1 | 15.2 | >60 | 28 | >60 |
Note for the Table: Compounds were test against Mevalonate kinase (MVK), Homoserine kinase (HSK), CDP-ME kinase, Glucokinase and Hexokinase, and IC50S are shown here. IC50S for GALK also listed